BioWorld

Cytospire raises £61M series A to target EGFR in solid tumors

Next-generation T-cell engager (TCE) specialist Cytospire Therapeutics Ltd. has raised £61 million (US$82.7 million) in a ...

Bracco Launches BubbleGen™ Early Access Program for Microbubble-Based Cell Selection and Activation at ISCT

Bracco Imaging, a global pharmaceutical company that develops, manufactures, and markets innovative healthcare solutions, ...
Pharmabiz

ModeX Therapeutics initiates clinical trial of tetraspecific antibody for treatment of B-cell lymphomas

ModeX Therapeutics initiates clinical trial of tetraspecific antibody for treatment of B-cell lymphomas: Weston, Massachusetts Friday, April 24, 2026, 16:00 Hrs [IST] ModeX Therap ...
Ventureburn

Cytospire Secures £61M Series A to Advance Cancer Drugs

Cytospire Therapeutics raises £61M in Series A funding to advance innovative cancer immunotherapy targeting gamma delta T ...
MarketersMEDIA Newsroom

KACTUS Publishes Framework for 2+1 and Trispecific TCE Scaffold Design

KACTUS has published a technical framework for engineering 2+1 and trispecific T-cell engager therapeutics, addressing structural scaffold challenges for drug discovery teams advancing beyond ...

Bracco Imaging: Bracco Launches BubbleGen Early Access Program for Microbubble-Based Cell Selection and Activation at ISCT

Bracco's new BubbleGen technology streamlines cell therapy manufacturing for one-step cell separation and activation with no magnetic residuals BubbleGen microbubbles can target specific cell ...